Anthropic’s Big AI Drug Discovery Announcement
Anthropic's new drug discovery programme marks a strategic shift from sole AI software provider to active R&D participant. Here's what it means for pharmaceutical innovation.
Articles, expert interviews, and insights from life sciences leaders
AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Read interview: How AI Is Reshaping Data Integrity in Pharma Manufacturing
Read interview: AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Read interview: AI in Pharma: Hype vs. What Actually Works
Read interview: How Pharmacy Innovation Is Changing Healthcare Delivery
Read interview: The Role of Regulatory Leadership in Healthcare
Read interview: Healthcare Supply Chains in Africa: Lessons from COVID-19
Read interview: How Cortical Implants Are Opening a New Era of Vision Restoration
Read interview: How Clinical Research Shapes Cardiac Device Innovation
Exclusive Pharmatica Content
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
Digital Measures in Clinical Trials: FDA vs EMA Pathways
Explore how novel digital measures gain regulatory acceptance in clinical trials, comparing FDA-structured pathways with EMA engagement-led frameworks.
FDA Draft Guidance on Gene Editing Safety (2026)
The FDA’s 2026 gene editing draft guidance could change your regulatory strategy. Explore the new NGS requirements for cell and gene editing therapies.
Next-Generation Sequencing for Cell Line Development in Biologics Manufacturing
Discover how next-generation sequencing in cell line development is improving biologics manufacturing, quality control, and regulatory confidence.
Real-Time Clinical Trials Are a Huge Competitive Advantage
Real-time clinical trials enable continuous data capture and faster decisions, improving how data is used in clinical trials. Here is what pharma leaders need to know.
Optimising Preclinical Pharmacology for Oncology NMEs
Over 90% of oncology NMEs that succeed in animal studies fail in clinical trials. This analysis examines how to optimise preclinical pharmacology models to improve translational success.
Could Biological Age Become Pharma's Most Important Biomarker?
New research shows biomarkers of biological age predict mortality and hospitalisation better than chronological age, opening new opportunities for pharma innovation.
FDA 2026 Draft Guidance on Alternatives to Animal Testing
The FDA's March 2026 draft guidance on alternatives to animal testing marks a pivotal shift in preclinical drug development. Here's what pharma R&D teams need to know.
Why Europe's Heatwave Is an Important Pharma Cold Chain Risk
Europe's 2026 heatwave is pushing pharmaceutical cold chain risk to the limit. Here is what supply chain leaders must do to protect drug integrity now.
Midjourney Medical: The AI Image Pioneer’s Unexpected Healthcare Play
Midjourney Medical is bringing AI, full-body imaging, and preventative care together. Could this unexpected move reshape healthcare delivery?
How Low Can They Go? Clinical Trial Success Rates
Clinical trial success rates have declined sharply over the past 20 years. This analysis examines what the data reveals about the drug approval rate and phase-by-phase attrition.
The AI Bioweapons Risk: We Cannot Afford to Look Away
The risk of AI being used to create a bioweapon is a serious concern for pharma biosecurity after researchers found AI-designed toxins can evade DNA screening. Here’s what you need to know about the AI and bioweapons risk.
